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Abstract
Background: Malignant esophageal obstruction leads to dysphagia, deterioration in quality of life, and
malnutrition. Traditional bedside nasogastric (NG) tube placement is very difficult under these circumstances.
However, endoscopically assisted NG tube placement under fluoroscopic guidance could be an alternative
option for establishing palliative enteral nutrition. This study aimed to compare the clinical outcomes of enteral
tube feeding and esophageal stenting for patients with malignant esophageal obstruction and a short life
expectancy.
Methods: Thirty-one patients were divided into 3 groups according to their treatment modality: NG tube (n = 12),
esophageal stent group (n = 10), and supportive care with nil per os (NPO) (n = 9). Enteral nutrition, clinical outcomes,
length of hospital stay, and median survival were evaluated.
Results: There were no significant baseline differences among the groups, except in age. The tube and stent groups
had significantly higher enteral calorie intake (p = 0.01), higher serum albumin (p < 0.01), shorter hospital stay (p = 0.01),
and longer median survival (p < 0.01) than the NPO group. The incidence of dislodgement in the tube group was
significantly higher than in the stent group (58 % vs. 20 %, respectively; p = 0.01). However, stenting costs more than
NG tube placement.
Conclusions: Palliative enteral feeding by NG tube is safe, inexpensive, and has a low complication rate. Endoscopically
assisted NG tube placement under fluoroscopic guidance could be a feasible palliative option for malignant
esophageal obstruction for patients who have a short life expectancy.
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Background
Esophageal cancer has a high mortality rate because
many patients are not diagnosed until the late stages of
disease [1]. Malignant esophageal obstruction, the condi-
tion wherein a tumor obstructs the esophagus [2], always
leads to dysphagia, which is one of the most troubling
and unbearable symptoms of this condition. Diagnosed
when the stenotic portion of the esophagus is less than
14 mm in diameter, dysphagia causes malnutrition and a
deterioration in quality of life [3]. Initially, patients de-
veloping a malignant esophageal obstruction will have
difficulty swallowing solid food. This can progress to dif-
ficulty swallowing semisolid food and, finally, difficulty
swallowing saliva and water [4]. These patients often
have a poor appetite, may experience significant weight
loss, and are likely to develop nutritional compromise. A
poor nutritional status is a significant prognostic factor
for mortality in patients with esophageal cancer [5].
Not only are patients with malignant esophageal ob-
struction harmed as a result of nutritional compromise,
the resulting cachexia accounts for profound adverse ef-
fect on patients’ quality and length of life [6]. Therefore,
nutritional supplementation is important to improve
the overall condition and quality of life of these and all
patients with esophageal cancer [7]. For patients with
terminal-stage esophageal cancer, the aim of nutritional
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therapy is palliative care, because the health-related
quality of life of these patients is very poor. Typically,
enteral feeding is considered superior to total parenteral
nutrition because parenteral nutrition has a higher risk of
complications and a higher expense [8]. However, for pa-
tients with advanced-stage esophageal cancer, establish-
ment of enteral nutrition is difficult.
The traditional bedside blind-passage method of naso-
gastric (NG) tube insertion fails in most cases of malig-
nant esophageal obstruction. In addition, percutaneous
endoscopic gastrostomy (PEG) might not be possible if the
endoscope cannot pass through the stenosis. An alternative,
esophageal stent placement improves dysphagia quickly [9]
and provides better long-term relief [10]. Hence, esophageal
stenting is considered an option for esophageal cancer
patients with severe dysphagia combined with a short
life expectancy or recurrent tumor growth after cancer
treatment [11]. For these patients, endoscopy-assisted NG
tube placement might be a suitable option for establish-
ment of enteral nutrition. In this study, we aimed to retro-
spectively evaluate and compare the clinical outcomes of
three palliative treatments: nutritional palliation with NG
tube placement under fluoroscopic guidance, esophageal
stenting, and a nil per os (NPO) regimen.
Methods
Patient selection
We reviewed the cases of 62 patients with malignant
esophageal obstruction from 2003 to 2013. Thirty-one
patients who underwent percutaneous endoscopic gas-
trostomy or surgical gastrostomy or jejunostomy were
excluded, leaving 31, all of whom had been diagnosed
with advanced-stage esophageal cancer requiring pal-
liative treatment owing to metastasis or poor medical
condition (unfitness to undergo surgery or chemotherapy).
All patients had dysphagia, causing nutritional comprom-
ise and deterioration in quality of life, the severity of which
was assessed by a dysphagia score. All patients’ Eastern
Cooperative Oncology Group (ECOG) performance score
was 4.
Endoscopically assisted esophageal stenting was the
first treatment considered for all patients. Esophageal
metallic stenting was not reimbursed by our health-
insurance system in Taiwan. If patients refused a stent
due to economic problems or their own choice, endoscop-
ically assisted NG tube placement, which was covered by
our health-insurance system, was suggested. If the patient
could not undergo either stenting or NG tube placement,
supportive palliative medical care was recommended,
and the patient was placed on an NPO regimen. Sup-
portive care with fluid hydration and minimal amount
of oral liquid diet and water were performed in the
NPO group.
Data collection
For each patient, data were collected on age, sex, body
mass index, nutritional condition (serum albumin at base-
line and 3–4 weeks later), tumor characteristics (location,
stage, and histology) (Table 1), presence of fistula, daily en-
teral caloric intake (on days 1, 3, 7, and 14 after the start
of treatment), daily intravenous fluid volume (on the day
prior to the procedure and days 1, 3, 7, and 14 afterward),
complications, duration of hospital stay, and median over-
all survival (Table 2). Esophageal tumor stage was deter-
mined according to the 7th American Joint Committee on
Cancer (AJCC) staging system.
Endoscopy-assisted NG tube placement
Patients were placed in the left lateral position for NG
tube placement. Oxygen saturation, blood pressure, and
heart rate were monitored during the procedure. All pa-
tients received a 12-Fr polyurethane feeding tube 114 cm in
length (Entube; Rusch, Duluth, GA, USA). The tube was
placed according to one of two methods: the guidewire
method and the push method.
In the guidewire method, the weighted tip of the feeding
tube was cut, and the outer wall of the tube was lubricated
with topical lidocaine (Xylocaine Jelly; AstraZeneca,
London, UK). The NG tube was flushed with water,
loaded with a guidewire (Hydra Jagwire; Boston Scientific,
Natick, MA, USA), inserted through the nostril, and
passed into the esophagus. A gastroscope was introduced
into the site of the stenosis (Fig. 1a).
In the push method [12], the NG tube, loaded with a
guidewire, was directly introduced through the stenosis
caused by the malignant esophageal obstruction. Initially,
the guidewire was introduced through the stenosis under
fluoroscopic guidance. Then, the NG tube was advanced
through the stenosis site directly along the guidewire
(Fig. 1b).
To confirm the position of the tube, contrast medium
was injected through the NG tube under fluoroscopy.
The gastroscope was withdrawn slowly out of the mouth
with the feeding tube kept in place to prevent retrograde
migration. The guidewire was removed after completion
of the procedure. An abdominal plain-film radiograph
was obtained to reconfirm the correct position of the
feeding tube in both methods (Fig. 1c).
Esophageal stenting
The malignant esophageal obstruction was assessed using
upper gastrointestinal endoscopy before esophageal stent
placement. First, a topical aerosol spray of lidocaine hydro-
chloride anesthetic was administered to the patient’s phar-
ynx. A guidewire was introduced through the endoscope
(GIF-Q260; Olympus, Tokyo, Japan), past the obstruction
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site, and into the distal part of the esophagus or stomach.
A covered metallic stent (Ultraflex; Boston Scientific)
was engaged by a guidewire under fluoroscopic guid-
ance. The esophageal stent length of 10, 12, or 15 cm
was selected based on the tumor size and length. After
placement, the stent was dilated and deployed under
fluoroscopic monitoring.
Statistical analysis
SPSS software version 20.0 (IBM, Armonk, NY, USA)
was used for all statistical analyses. One-way ANOVAs
were used to analyze the relationships between the three
groups. Student’s t-test, the χ2-test, and Fisher’s exact
test were used to analyze the relationship between the
NG group and the stent group. Overall median survival
Table 1 Patients’ characteristics
NG tube Esophageal stent NPO P-value
(n = 12) (n = 10) (n = 9)
Age in years 72.6 ± 14.1 58.0 ± 9.4 61.4 ± 7.8 0.01
Gender (M/F) 10/2 9/1 8/1 0.88
BMI 19.0 ± 3.3 18.1 ± 2.6 17.4 ± 2.6 0.45
Cancer stage 0.18
III 2 0 0
IV 10 10 9
Histology 0.07
SCC 9 10 9
ADC 3 0 0
Dysphagia score 3.6 ± 0.5 3.1 ± 0.6 3.8 ± 0.4 0.02
3 5 8 2
4 7 2 7
Fistula
Yes 1 6 0 <0.01
No 11 4 9
Albumin (g/dL) 2.8 ± 0.4 2.8 ± 0.5 2.5 ± 0.2 0.15
Indication for palliation 0.05
Metastasis 10 (83 %) 10 (100 %) 5 (56 %)
Poor medical condition 2 (17 %) 0 (0 %) 4 (44 %)
NG tube nasogastric tube, NPO nil per os, SCC squamous cell carcinoma, ADC adenocarcinoma
Table 2 Clinical outcomes and complications
NG tube Esophageal stent NPO P-value
(n = 12) (n = 10) (n = 9)
Albumin, g/dL 3.1 ± 0.5 3.0 ± 0.5 2.1 ± 0.4 <0.01
EN intake, dL/day 11.8 ± 4.9 10.9 ± 3.5 3.6 ± 1.9 0.01
IV fluid volume, dL/day 9.9 ± 4.9 9.4 ± 3.7 13.5 ± 3.3 0.08
LOH, days 19 ± 15 12 ± 11 39 ± 18 0.01
Survival, days 122a 133a 51 <0.01
Complications 22 21 9
Aspiration pneumonia 7b 5b 9 0.38
Dislodgment 7c 2c 0 0.01
Chest pain 2 3 0 0.21
Perforation 0 0 0
Hemorrhage 0 0 0
ap = 0.56 between NG tube group and esophageal stent group. bp = 0.63 between NG tube group and esophageal stent group. cp = 0.01 between NG tube group
and esophageal stent group. NG tube nasogastric tube, NPO nil per os, EN enteral nutrition, PN parenteral nutrition, LOH length of hospital stay, IV intravenous
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was calculated from the date of malignant esophageal
obstruction diagnosis until death or the last follow-up.
Certain parameters, including age, presence of fistula,
and dysphagia score, were entered into a Cox regression
model to analyze their relative prognostic importance
and to plot survival curves, which were tested by the
log-rank test. p < 0.05 was considered statistically signifi-
cant for all analyses. The clinical data were obtained
from our database which had been established in a
double blind process. In addition, the Institutional Re-
view Board of the Tri-Service General Hospital approved
the use and analysis of clinical data (IRB: 2-104-05-
030) (Additional file 1).
Results
Baseline characteristics and duration of hospital stay
The 31 patients ranged in age from 38 to 88 years with a
mean of 64.7 years. There were 27 men and 4 women.
When malignant esophageal obstruction was diagnosed,
the cancer was AJCC stage IIIC in 3 patients and stage
IV in the remaining 28. Patients were divided into three
groups according to treatment modality: the NG feeding
tube group (n = 12), the esophageal stent group (n = 10),
and the group assigned to supportive care under an NPO
regimen (n = 9) (Table 1). In the NG feeding tube group,
the tube was inserted using the push method in 8 patients
and the guidewire method in the remaining 23. There
were no significant differences in baseline clinical features
among the three groups, except in age (Table 1); the three
groups were similar with regard to sex distribution, body
mass index, dysphagia score, location of tumor, AJCC
stage, tumor histology, and baseline serum albumin. The
average duration of hospital stay was 19 days in the NG
feeding tube group, 12 days in the esophageal stent group,
and 39 days in the NPO group (p = 0.01; Table 2).
Daily enteral caloric intake and serum albumin
There was a significant difference in enteral caloric in-
take among the three groups (p = 0.01, Table 2), but no
significant difference was found between the NG feeding
tube group and the esophageal stent group. Serum albu-
min data were available for 11 of the 12 patients who re-
ceived an NG feeding tube, 8 of the 10 patients who
received an esophageal stent, and all 9 patients who were
placed on an NPO regimen. Compared with baseline,
serum albumin at 3–4 weeks was decreased only in the
NPO group. There were significant differences in serum
albumin among the three groups after the procedure
(3.1 g/dL in the NG feeding group, 3.0 g/dL in the stent
group, 2.1 g/dL in the NPO group; p < 0.01, Table 2). We
recorded enteral caloric intake on the day before initiation
of palliative treatment and on the first, third, seventh, and
fourteenth days of treatment (Fig. 2). The calorie of enteral
nutritional formula was one Kcal/ml.
Survival
Median survival after diagnosis of malignant esophageal
obstruction was 91 days overall: 122 days for the 12
Fig. 1 Representative images before and after endoscopy-assisted nasogastric tube placement (a) Esophagogastroduodenoscopy demonstrating
nearly total obstruction of the esophagus by a tumor. b NG tube (black arrowhead) passed through the site of the obstruction. c Abdominal
plain-film radiograph showing that the feeding tube is in the stomach (white arrow); reconfirmed using contrast medium
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patients who received an NG feeding tube, 133 days for
the 10 patients who received an esophageal stent, and
51 days for the 9 patients who received supportive care
under an NPO regimen. The length of hospital stay was
19 days in the NG group, 12 days in the esophageal stent
group, and 39 days in the NPO group (Table 2). Compared
to the NG feeding tube group and the esophageal stent
group, the NPO group had significantly inferior overall sur-
vival (p < 0.01; Table 2). However, there was no significant
difference in overall survival between the NG feeding tube
group and the esophageal stent group (p = 0.56, Table 2).
After adjustment for age, dysphagia, and presence of fistula,
a Cox regression model found a significant difference
among the three groups (Table 3). Patients in the NG group
had an adjusted hazard ratio of 0.09 (95 % confidence inter-
val 0.02–0.36), and patients in the stent group had an
adjusted hazard ratio of 0.16 (95 % confidence interval
0.03–0.84). However, there was no significant difference
in median overall survival between the NG feeding tube
group and the esophageal stent group after adjustment
for other prognostic factors.
On multivariate Cox regression analysis, nutritional
palliation by endoscopically guided NG tube placement
(p = 0.03, hazard ratio 0.09, 95 % confidence interval
0.02–0.36) was an independent predictive factor of bet-
ter overall survival in patients with advanced esophageal
cancer (Table 3). Survival curves, adjusted for the Cox
regression, were plotted for the tube and stent groups
(Fig. 3)
Complications
NG feeding tube placement was technically successful in
all patients without severe procedure-related complica-
tions such as perforation, massive bleeding, or mortality.
Similarly, stent placement was successful in all patients,
without severe procedure-related complications. Two
patients in the tube group and 3 in the stent group experi-
enced post-procedural retrosternal pain and chest discom-
fort. The most common disease-related complication in
the tube group was aspiration pneumonia (58 %), which
also occurred in 5 patients (50 %) in the esophageal stent
group and all 9 patients (100 %) in the NPO group; there
was no significant difference in the incidence of aspiration
pneumonia among the NG feeding tube group and the
esophageal stent group (p = 0.63; Table 2). Following the
procedure, 7 patients in the NG tube group (75 %) and 2
in the stent group (29 %) experienced dislodgment and re-
quired a repeat procedure. The average duration of dis-
lodgment in NG tube group was 46.3 days. All repeated
procedures for dislodgment were successful. Overall, there
were no differences in the incidence of complications be-
tween the NG feeding tube group and the esophageal stent
group, except for dislodgement (p = 0.01; Table 2).
Discussion
The survival benefit of endoscopically assisted NG tube
placement under fluoroscopy as compared with placement
of a metal esophageal stent has not been well documented.
Our study is the first report to compare median survival
among three groups receiving respectively an NG tube, an
esophageal stenting, and supportive care under an NPO
regimen, as well as the first to reveal the significantly
shorter median survival, in comparison with the stent and
tube groups, of patients placed on an NPO regimen with
only supportive care. Moreover, we are the first to observe
Fig. 2 Daily enteral caloric intake for patients with an NG tube and
those with an esophageal stent. Intake increased progressively in both
groups. Each point and vertical bar represents the mean ± standard
deviation. *P < 0.05
Table 3 Crude and adjusted hazard ratios for overall survival
Group Crude HR 95 % CI Adjusted HR 95 % CI
NPO Reference Reference
NG tube 0.16* 0.05–0.50 0.09* 0.02–0.36
Esophageal stent 0.12* 0.03–0.40 0.16* 0.03–0.84
Adjusted for age, fistula and dysphagia score
*p < 0.05. Comparisons are made using NPO group as reference
NG tube nasogastric tube, NPO nil per os, HR hazard ratio, CI confidence interval
Fig. 3 Survival curve plotted using Cox regression analysis
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the lack of significant difference in overall survival patients
receiving an NG feeding tube and those receiving an
esophageal stent.
Advanced esophageal cancer has a poor prognosis, with
a 5-year survival rate of 10–15 %. Malignant esophageal
obstruction resulting from such cancer can cause malnu-
trition, increases mortality risk, and reduces tolerance to
radiotherapy and chemotherapy [13]. The harmful effect
of cachexia, resulting from the obstruction, on severity of
illness and mortality risk is of particular concern. An
Asian retrospective study reported that the median overall
survival of patients with AJCC stage IV cancer was 125 days
[14]. Because advanced esophageal cancer is not curable,
palliative treatment is required, particularly to improve
quality of life and correct dysphagia and poor nutrition
[15]. In fact, more than 50 % of patients with esophageal
cancer have an inoperable condition at presentation and
require palliation for poor nutrition [16]. Palliative care
should result in a low complication rate in these patients
and is usually performed during a limited hospital stay be-
cause their life expectancy is short [17].
European nutrition societies recommend using enteral
nutrition as first-line support in patients with a functional
gut. [18]. If this route is not available, then parenteral nu-
trition may be selected. However, parenteral nutrition
should not be given regularly and a thorough assessment
needs to be done before the initiation of parenteral nutri-
tion. Full consideration of assessment includes patients’
clinical condition, psychosocial aspect and potential eco-
nomic constraints [19]. When feeding routes are in place,
it is easier to provide patients with medication in addition
to nutrition and hydration. Feeding has a well-being pur-
pose in some patients, particularly in the last period of life.
Preserving nutrition and daily functional activity is one
goal of enteral feeding, and relieving hunger and thirst is
another goal. Refractory cachexia is characteristic of low
performance score and expected survival of less than
3 months. If the patients are in refractory cachexia stage,
therapeutic interventions, such as NG tube feeding or
esophageal stenting, may alleviate the hunger and eating-
related distress of patients and families [6]. Some evidence
also supports clinical significance for the establishment of
enteral nutrition for patients with esophageal cancer.
Compared with total parenteral nutrition, enteral nutrition
has been found to have a lower frequency of metabolic
problems [20]. It is important for maintaining the normal
mucosal barrier of the gut, which blocks the invasion of
gut flora and prevents immune compromise caused by
toxic side effects [21]. Endoscopically assisted NG tube
placement under fluoroscopic guidance is a widely used
way to establish enteral nutrition. However, instead of
enteral nutrition, metal esophageal stenting, which has
been used since the 1990s, is currently the main option
to palliate malignant esophageal obstruction [22].
Homs et al. suggested that stent placement be reserved
for patients with severe dysphagia and a short life expect-
ancy or for those with poor response to brachytherapy;
they found the median survival after stent placement to
be 145 days [16]. Grilo et al. showed that percutaneous
endoscopic gastrostomy (PEG) may be a suitable enteral
nutrition technique in patients unsuitable for esophageal
stenting, and they reported mean survival after PEG to be
5.9 months [23]. Ferraz et al. reported that overall median
survival after gastrostomy for patients with advanced
esophageal cancer was 61 days (range 1 to 551 days) [24].
When stenting, radiation, and PEG are technically not
feasible, adequate caloric intake should be maintained by
nutritional support with an NG feeding tube [25].
Advanced TNM stage, weight loss, dysphagia, fistula,
and advanced age are known independent indicators of
poor prognosis for patients with esophageal cancer [26].
In the present study, median overall survival of patients
in the NPO group was approximately half that of pa-
tients in the NG group and esophageal stent group. A
Cox regression model found significant differences in
survival among the three groups with regard to age, dys-
phagia, and presence of fistula. However, no significant
difference in median overall survival between the tube
group and the stent group was demonstrated after ad-
justment for other potential prognostic factors.
Compared to the NG feeding tube group and the
esophageal stent group, the NPO group had significantly
longer length of hospital stay (p = 0.01; Table 2). After
establishment of enteral feeding, the need of intravenous
fluids became less. The administration of home paren-
teral nutrition in incurable cancer patients was a debate
among different specialists and in the field of bioethics
[27]. The patients with NG feeding or esophageal stent
were cared more easily by their care-giver at home with-
out intravenous fluids support.
Establishment of enteral nutrition is another predictor
of median overall survival in patients with advanced
esophageal cancer. It has many advantages as a treatment
in patients with advanced malignant obstruction, includ-
ing physiological response, immunocompetence, increased
quality of life, and cost-effectiveness [28]. However, in our
study, enteral nutrition and esophageal stenting produced
similar benefits, with both improving overall survival.
Lazaraki et al. reported that metal esophageal stenting was
a superior choice for malignant esophageal dysphagia,
with a low rate of procedure-related complications (0–
17 %) and low procedure-related mortality (0–2 %)
[29]. In the present study, the rate of procedure-related
complications in both groups was very low, showing
that endoscopy-assisted NG tube placement and metal
esophageal stenting are safe even in patients who have
been heavily treated or are in a late stage of disease.
However, Nicolas et al. found the incidence of aspiration
Yang et al. BMC Palliative Care  (2015) 14:58 Page 6 of 8
pneumonia in patients with an NG feeding tube to be
53 %, a result of gastroesophageal reflux related to the
presence of the tube; in our study, the incidence of aspir-
ation pneumonia in the tube group was 58 %, which is
comparable. There was no significant difference in the in-
cidence of aspiration pneumonia between the tube group
and the stent group. However, the incidence of dislodg-
ment in the tube group was significantly higher than in
the stent group (58 % vs. 20 %, p = 0.01; Table 2). Food
bolus obstruction and removal of the NG tube by the pa-
tient were the main reasons for this.
A 2004 study by Homs et al. showed that there was no
significant difference in median survival between patients
who underwent brachytherapy (155 days) and patients
who underwent stent placement (145 days), although pa-
tients who underwent brachytherapy had better quality of
life after a follow-up of at least 3 months [30]. However,
brachytherapy may not be suitable for advanced esopha-
geal cancer patients with a short life expectancy who need
quick establishment of enteral nutrition or for patients
who have previously failed brachytherapy [31]. NG tube
placement and PEG should be reserved for patients with
short life expectancy and those in poor medical condition.
Although PEG is thought to be the better option for a
long-term feeding route, NG tube placement and esopha-
geal stenting may play a role when the endoscope cannot
pass the obstruction site or when PEG fails. Shukla et
al. reported a success rate of approximately 75 % for
endoscopy-assisted NG tube placement [32]. In our
study, NG tube placement was attempted in 14 patients.
Two patients failed because of nearly complete obstruc-
tion of the tumor site and were treated with supportive
care under an NPO regimen. As we used fluoroscopic
guidance, our tube placement success rate was 86 %, an
increase from that reported by Shukla et al. [32].
Squamous cell carcinoma of the esophagus is associ-
ated with lower socioeconomic status [33], and NG tube
placement (US$235) costs less than esophageal stenting
(US$2,205). Therefore, endoscopically assisted NG tube
placement under fluoroscopic guidance might be an
affordable alternative for patients who cannot afford a
metal esophageal stent.
There are some limitations to our study. First, its
retrospective design and small sample size mean that
large prospective cohort studies are needed to confirm
the impact of endoscopically assisted NG tube place-
ment in patients with advanced malignant esophageal
obstruction. Second, data on the patients’ symptoms and
follow-up were obtained from reviews of medical re-
cords, which might introduce selection bias. Third, be-
cause the Taiwanese national health insurance system
does not reimburse patients for metal esophageal stents,
patients in the esophageal stent group might have had
better socioeconomic status than those in the NG and
NPO groups. Fourth, we did not assess quality of life.
Metal esophageal stenting might be preferable for pa-
tients with a short life expectancy who require quick
relief from dysphagia [30], as eating by mouth allows
patients to taste the food, and this might be related to
quality of life. Fifth, it was difficult to calculate total caloric
intake from enteral source and parenteral source during
hospitalization and home-care period. There was no sig-
nificant difference (p = 0.08; Table 2) in the amount of
intravenous fluids among the three groups. The patients
who received peripheral parenteral nutrition (PPN) after
establishment of the enteral route are two in the NG tube
group, one in the esophageal stent group, and two in the
NPO group. No patient received total parenteral nutrition.
In the NG tube group and the esophageal stent group,
parenteral nutrition was stopped one day after establish-
ment of enteral route. One patient in NPO group received
1800 ml of PPN for 5 days and stopped PPN because of
pulmonary edema. The other patient in NPO group re-
ceived 1200 ml PPN for 16 days and stopped PPN because
of patient and family’s decision. The average mean survival
in NPO group with PPN was 62 days, which was superior
to mean survival in NPO group. Insufficient nutrition
support may be one of the reasons of poor prognosis in
NPO group. The amount of enteral intake, however, was
increased significantly in the NG tube group and the
esophageal stent group. The procedure may also alleviate
the hunger and eating-related distress of incurable cancer
patients and families [6].
Conclusion
In conclusion, both endoscopically assisted NG tube place-
ment under fluoroscopic guidance and esophageal stenting
significantly improved the survival of patients with malig-
nant esophageal obstruction, with no significant difference
between the treatments. Palliative enteral feeding by NG
tube is safe, inexpensive, and has a low complication rate.
Therefore, we suggest that endoscopy-assisted NG tube
placement under fluoroscopic guidance can be considered
as an alternative method of palliative treatment for malig-
nant esophageal obstruction for patients who have a short
life expectancy or who are unable to receive esophageal
stenting due to cost concerns or personal choice.
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